Document:

Commitment Letter dated as of May 31, 2007

 Exhibit 10.11 
 EXECUTION VERSION 
 JPMORGAN CHASE BANK, N.A. 
 J.P. MORGAN SECURITIES INC. 
 270 Park Avenue 
 New York, NY 10017 
 CONFIDENTIAL 
 May 31, 2007 
  

			
	PharMerica, Inc.	  	
	1300 Morris Drive, Suite 100	  	
	Chesterbrook, PA 19087	  	

			
	Attention of:	  	Mr. Jack Quinn
		  	Vice President and Corporate Treasurer

  

			
	Kindred Pharmacy Services, Inc.	  	
	680 South Fourth Street	  	
	Louisville, KY 40202	  	

			
	Attention of:	  	Mr. Richard A. Lechleiter
		  	Executive Vice President and Chief Financial Officer

  

			
	Safari Holding Corporation	  	
	1901 Campus Place	  	
	Louisville, KY 40219	  	

			
	Attention of:	  	Mr. Gregory S. Weishar
		  	Chief Executive Officer

 PharMerica Corporation 
 $375,000,000 Senior Secured Credit Facilities 
 Commitment Letter

 Ladies and Gentlemen: 
 PharMerica, Inc.,
a Delaware corporation (“PharMerica LTC”), and Kindred Pharmacy Services, Inc., a Delaware corporation (“KPS”), have advised JPMorgan Chase Bank, N.A. (“JPMCB”) and J.P. Morgan Securities Inc.
(“JPMorgan” or the “Arranger”; JPMCB and JPMorgan are collectively referred to as “we” or “us”) that, pursuant to a Master Transaction Agreement dated as of October 25, 2006
(such agreement, together with the related definitive documentation, the “Transaction Agreement”), by and among AmerisourceBergen Corporation, a Delaware corporation (“AmerisourceBergen”), 

 
PharMerica LTC, Kindred Healthcare, Inc., a Delaware corporation (“Kindred”), Kindred Healthcare Operating, Inc., a Delaware corporation and
wholly owned subsidiary of Kindred (“KHO”), KPS, Safari Holding Corporation, a Delaware corporation (“Newco” and, together with PharMerica LTC and KPS, “you”), Hippo Merger Corporation, a Delaware
corporation and wholly owned subsidiary of Newco (“Hippo Merger Sub”), and Rhino Merger Corporation, a Delaware corporation and wholly owned subsidiary of Newco (“Rhino Merger Sub”): (a) (i) Pharmacy
Corporation of America, a Delaware corporation and a wholly-owned subsidiary of PharMerica LTC, will transfer its wholly owned subsidiaries PMSI, Inc. and TMESYS, Inc., which conduct AmerisourceBergen’s workers’ compensation services
businesses, to AmerisourceBergen or a subsidiary of AmerisourceBergen that is not a subsidiary of PharMerica LTC, (ii) each of AmerisourceBergen, PharMerica LTC, Kindred and KPS will take all actions necessary to cause AmerisourceBergen and
Kindred, respectively, to own all of PharMerica LTC’s and KPS’s right, title and interest in all assets that are not owned, used or held for use primarily in connection with the institutional pharmacy business of PharMerica LTC or KPS,
respectively, and to assign and transfer to AmerisourceBergen and Kindred, respectively, all of PharMerica LTC’s and KPS’s liabilities not relating to its institutional pharmacy business and (iii) each of AmerisourceBergen, PharMerica
LTC, Kindred and KPS will take all actions necessary to cause PharMerica LTC and KPS, respectively, to own all of AmerisourceBergen’s and Kindred’s right, title and interest in all assets used or held for use primarily in connection with
the institutional pharmacy business that are not already owned by PharMerica LTC and KPS, and to assign and transfer to PharMerica LTC and KPS, respectively, all of AmerisourceBergen’s and Kindred’s liabilities relating to its
institutional pharmacy business that are not already liabilities of PharMerica LTC or KPS, respectively, (b) using the proceeds of the Spinco Loans (as defined below), PharMerica LTC will make a cash distribution to AmerisourceBergen and KPS
will make a cash distribution to KHO, which cash distributions will total not more than $250,000,000 (together, the “Spinco Distributions”), (c) immediately following the Spinco Distribution by KPS but prior to the spin-off of
KPS described in clause (d), KHO will distribute all the outstanding shares of KPS to Kindred, (d) immediately following the transactions described in clauses (b) and (c), AmerisourceBergen and Kindred will each deliver a single
certificate representing all of the outstanding shares of PharMerica LTC and KPS, respectively, to a distribution agent for the benefit of the stockholders of AmerisourceBergen and Kindred, respectively, (together, the “Spin-offs”),
(e) immediately following the Spin-offs, Hippo Merger Sub will merge with and into PharMerica LTC, with PharMerica LTC as the surviving corporation, and Rhino Merger Sub will merge with and into KPS, with KPS as the surviving corporation
(together, the “Mergers”), and each of PharMerica LTC and KPS will thereby become a wholly owned direct subsidiary of Newco, (f) pursuant to the Mergers, all shares of PharMerica LTC and KPS will be converted into shares of
Newco and shares of Newco will, as consideration for the Mergers, be distributed to the stockholders of AmerisourceBergen and Kindred, and (g) immediately following the foregoing transactions, Newco will use a portion of the proceeds of term
loans under the Permanent Facilities (as defined below) to repay the Spinco Loans. Each capitalized term used but not defined herein shall have the meaning assigned to it in the Summary of Principal Terms and Conditions attached hereto as Exhibit
A (including the annexes thereto, the “Term Sheet”). 
  

 2 

 AmerisourceBergen and Kindred have further advised JPMCB and the Arranger that (a) in order to
consummate the Spinco Distributions, PharMerica LTC and KPS will require the senior secured term loans (together, the “Spinco Loans”) described in Part I of the Term Sheet in an aggregate principal amount of up to $250,000,000 and
(b) immediately following the Mergers, Newco will require the senior secured facilities described in Part II of the Term Sheet in an aggregate principal amount of $375,000,000 (the “Permanent Facilities”). The Spinco Loans and
the Permanent Facilities are collectively referred to herein as the “Facilities”. 
 JPMCB is pleased to advise you of its
commitment to provide (i) up to $75,000,000 of the aggregate principal amount of the Permanent Facilities, which amount shall be allocated ratably between the Revolving Facility and the Term Facility, and (ii) its ratable share of the
Spinco Loans based on the amount of its commitment under the Term Facility, in each case on the terms and subject to the conditions set forth or referred to in this Commitment Letter (this “Commitment Letter”) and in the Term Sheet,
and subject to the syndication of the balance of the Facilities to other financial institutions. 
 You hereby appoint JPMorgan to act, and
JPMorgan hereby agrees to act, as sole lead arranger and sole bookrunner for the Facilities on the terms and subject to the conditions set forth or referred to in this Commitment Letter and in the Term Sheet. In such capacities, JPMorgan agrees to
use its commercially reasonable efforts to assemble a syndicate of Lenders (as defined below) willing to provide the Facilities on such terms and subject to such conditions. You also hereby appoint JPMCB to act, and JPMCB hereby agrees to act, as
sole administrative agent and collateral agent for the Facilities on the terms and subject to the conditions set forth or referred to in this Commitment Letter and the Term Sheet. Each of JPMorgan and JPMCB, in such capacities, will perform the
functions and exercise the authority customarily performed and exercised by it in such roles. It is agreed that, except as set forth in this Commitment Letter, in the Term Sheet or in the Fee Letter (as defined below), no additional agents,
co-agents, arrangers, co-arrangers, bookrunners, joint bookrunners, managers or co-managers will be appointed, no other titles will be awarded and no compensation will be paid in connection with the Facilities unless you and we shall so agree.

 JPMCB reserves the right, prior to or after the execution of definitive documentation for the Facilities (the “Loan
Documentation”), to syndicate all or a portion of its commitment hereunder, pursuant to a syndication to be managed by the Arranger in consultation with you, to one or more financial institutions reasonably satisfactory to you (together
with JPMCB, the “Lenders”) that will become parties to such Loan Documentation. 
 The Arranger will manage all aspects of
the syndication in consultation with you, including selection of prospective Lenders, determination of when prospective Lenders will be approached, the timing of acceptance of the Lenders’ commitments, any 

  

 3 

 
naming rights, the allocation of the commitments among the Lenders and the amount and distribution of fees among the Lenders. You understand that the
Arranger intends to commence syndication efforts for the Facilities promptly after the date hereof. You agree actively to assist the Arranger in completing a syndication reasonably satisfactory to the Arranger and to you between the date hereof and
the date that is 60 days after the Closing Date (the “Syndication Termination Date”). Such assistance shall include (a) your using commercially reasonable efforts to ensure that syndication efforts benefit materially from your
and your subsidiaries’ existing lending and investment banking relationships, (b) direct contact between your, PharMerica LTC’s and KPS’s senior management, representatives and advisors on the one hand, and the prospective
Lenders, on the other hand, at mutually agreeable times and locations, (c) your assistance in the preparation of a customary Confidential Information Memorandum and other customary marketing materials reasonably requested by the Arranger to be
used in connection with the syndication of the Permanent Facilities (collectively with the Term Sheet, the “Information Materials”) and (d) the hosting, with the Arranger, of one or more meetings of or a reasonable number of
conference calls at mutually agreeable times with prospective Lenders. In addition, you agree promptly to prepare and provide to us at or prior to the Syndication Termination Date all such information with respect to PharMerica LTC and KPS and their
respective subsidiaries and the transactions contemplated hereby, including all financial projections, estimates and forecasts and other forward-looking information (the “Projections”), as the Arranger may reasonably request in
connection with the structuring, arrangement and syndication of the Facilities, which in the case of pro forma financial information and the Projections will be comprised of the materials delivered under paragraphs 5 and 6 of Annex III to Exhibit A
hereto and shall only be provided to Lenders subject to customary IntraLinks confidentiality provisions. 
 You hereby represent and warrant
(and it shall be a condition to JPMCB’s commitments and the Arranger’s agreements hereunder) that, to the best of your knowledge, (a) all information other than the Projections (the “Information”) and information of a
general economic or general industry nature that has been or will be made available to us by or on behalf of you or any of your representatives or affiliates, taken as a whole, is or will be, when furnished, correct in all material respects and does
not or will not, when furnished, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not misleading in any material respect in light of the circumstances under
which such statements are made (after giving effect to all supplements thereto) and (b) the Projections that have been or will be furnished to us by or on behalf of you or any of your representatives or affiliates have been and will be prepared
in good faith based upon assumptions that are reasonable at the time made and at the time the related Projections are furnished to us, it being recognized by us that such Projections as to future events are not to be viewed as facts and that actual
results during the period or periods covered by any such Projections may differ significantly from the projected results and such differences may be material. You agree that if, at any time prior to the earlier of the Syndication Termination Date or
the completion of the primary syndication of the Facilities (as reasonably determined by the Arranger), the condition in the preceding sentence would not be satisfied if the Information 

  

 4 

 
and Projections were being furnished at such time, then you will promptly notify us and supplement the Information and the Projections so that such condition
would be satisfied under those circumstances. In structuring, arranging and syndicating the Facilities, we will be entitled to use and rely primarily on the Information and the Projections without responsibility for independent verification. It is
understood and agreed that the representations made hereunder by PharMerica LTC relate solely to PharMerica LTC and its affiliates; the representations made hereunder by KPS relate solely to KPS and its affiliates; and the representations made by
Newco relate solely to itself and those persons which shall be its affiliates after giving effect to the transactions contemplated hereby. 
 As consideration for JPMCB’s commitments and the Arranger’s agreements hereunder, you agree to pay the nonrefundable fees set forth in the Term Sheet and in the Fee Letter dated as of the date hereof, among you, JPMCB and JPMorgan
and delivered herewith with respect to the Facilities (the “Fee Letter”), as and when provided therein. 
 JPMCB’s
commitments and the Arranger’s agreements hereunder to provide the services described herein are further subject to (a) there not occurring or become known to us any event, condition or circumstance that constitutes, or could reasonably be
expected to result in, a material adverse effect or a material adverse change in or on the business, operations, assets, financial condition or results of operations of PharMerica LTC, KPS and their respective subsidiaries, taken as a whole,
(i) determined, in the case of PharMerica LTC and its subsidiaries, since September 30, 2006, and (ii) determined, in the case of KPS and its subsidiaries, since December 31, 2006, (b) our not having discovered or otherwise
becoming aware after the date hereof of any information or other matter not previously disclosed to us that, in the reasonable judgment of the Arranger, is inconsistent in a material and adverse manner with the information provided to us prior to
the date hereof, of the business, operations, assets, financial condition or results of operations of PharMerica LTC, KPS and their respective subsidiaries, taken as a whole, (c) prior to and during the syndication of the Facilities, there
shall be no competing offering, placement or arrangement of any debt securities or bank or other credit facilities by or on behalf of PharMerica LTC, KPS, Newco or any of their subsidiaries, and (d) the negotiation, execution and delivery of
the Loan Documentation on terms and subject to conditions consistent with this Commitment Letter, the Term Sheet and the Fee Letter and otherwise mutually satisfactory. Those matters that are not covered by or made clear under the provisions hereof
and of the Term Sheet are subject to the approval and agreement of each of us and you. 
 You agree (a) to indemnify and hold harmless
each of us and our affiliates and our and our affiliates’ officers, directors, employees, agents, advisors and controlling persons (each, an “indemnified person”) from and against any and all losses, claims, damages,
liabilities and expenses, joint or several, to which any such indemnified person may become subject arising out of or in connection with this Commitment Letter, the Term Sheet, the Fee Letter, the Facilities, the use of proceeds thereof, the
transactions contemplated hereby or any related transaction or any claim, litigation, investigation or proceeding relating to any of the foregoing, regardless of whether based in contract, tort or 

  

 5 

 
any other theory, whether brought by you, your affiliates or any other person or whether any indemnified person is a party thereto, and to reimburse each
indemnified person upon demand for any reasonable, documented, out-of-pocket legal or other expenses incurred in connection with investigating or defending any of the foregoing; provided that the foregoing indemnity will not, as to any
indemnified person, apply to losses, claims, damages, liabilities or related expenses to the extent they are found by a final, non-appealable judgment of a court of competent jurisdiction to have resulted from the wilful misconduct, bad faith or
gross negligence of such indemnified person or from the breach by such indemnified party of its agreements hereunder and (b) to reimburse each of us and our affiliates upon demand for all reasonable documented out-of-pocket expenses (including,
without limitation, due diligence expenses, consultants’ fees, syndication expenses, travel expenses and reasonable fees, charges and disbursements of counsel) incurred in connection with the Facilities and any related documentation (including,
without limitation, the preparation of this Commitment Letter, the Term Sheet, the Fee Letter and the Loan Documentation) or the administration, amendment, modification or waiver thereof. No indemnified person shall be liable for (x) any
damages arising from the use by others of Information or other materials obtained through electronic telecommunications or other information transmission systems (including the internet), except for damages due to wilful misconduct, bad faith or
gross negligence of such indemnified person (it being understood that this clause (x) is not intended to exculpate any knowing and intentional breach of any confidentiality agreement), or (y) any special, indirect, consequential or
punitive damages in connection with the Facilities or its activities related to the Facilities. 
 You acknowledge that each of us and our
affiliates may be providing debt financing, equity capital or other services (including, without limitation, financial advisory services) to other entities that have or may have interests conflicting with your interests with respect to the
transactions described herein or otherwise. Each of us agrees that neither it nor any of its affiliates will use confidential information obtained from you or your subsidiaries in the course of the transactions contemplated hereby (and not otherwise
in its or any of its affiliates’ possession or publicly available) in connection with its or any of its affiliates’ performance of services for other companies, and neither it nor any of its affiliates will furnish any such information to
other companies. You also acknowledge that none of us or any of our affiliates has any obligation to use in connection with the transactions contemplated hereby, or furnish to you, confidential information obtained by us or any of our affiliates
from other persons. 
 You acknowledge and agree that in connection with all aspects of the transactions contemplated hereby, including the
Facilities, and any communications in connection therewith, you and your subsidiaries and affiliates, on the one hand, and each of us and any of our affiliates through which we may be acting, on the other hand, will have a business relationship that
does not create, by implication or otherwise, any fiduciary duty on the part of any of us or any of our affiliates, and each party hereto agrees that no such duty will be deemed to have arisen in connection with any such transactions or
communications. You further acknowledge that JPMCB and the Arranger are full service securities firms and they may from time to time effect transactions, for their own or their 

  

 6 

 
affiliates’ account or the account of customers, and from time to time hold positions in loans, securities or options on loans or securities of you and
your affiliates and of other companies that may be the subject of the transactions contemplated by this Commitment Letter. 
 This Commitment
Letter shall not be assignable by you without our prior written consent (and any purported assignment without such consent shall be null and void), is intended to be solely for the benefit of the parties hereto (and the indemnified persons) and is
not intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto (and the indemnified persons). This Commitment Letter may not be amended or any provision hereof waived or modified except by an
instrument in writing signed by each of the parties hereto. This Commitment Letter may be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Delivery of
an executed signature page of this Commitment Letter by facsimile or other electronic imaging means shall be effective as delivery of a manually executed counterpart hereof. This Commitment Letter (including the Term Sheet) and the Fee Letter are
the only agreements that have been entered into by the parties hereto with respect to the Facilities and set forth the entire understanding of the parties hereto with respect to such matters. Each of us may perform the duties and activities
described herein through any of our affiliates and the indemnification and expense reimbursement provisions shall apply with equal force and effect to any such affiliate so performing any such duties and activities. It is understood and agreed that
all obligations of PharMerica LTC and KPS hereunder (including in respect of syndication assistance and indemnification) prior to the Closing Date shall be several and not joint. 
 This Commitment Letter shall be governed by, and construed in accordance with, the laws of the State of New York. Each of the parties hereto irrevocably
and unconditionally submits to the non-exclusive jurisdiction of any state or Federal court sitting in the City of New York, Borough of Manhattan, over any suit, action or proceeding arising out of or relating to the transactions contemplated hereby
or this Commitment Letter. Each of the parties hereto hereby agrees that service of any process, summons, notice or document by registered mail addressed to it shall be effective service of process for any suit, action or proceeding brought in any
such court. Each of the parties hereto, to the fullest extent permitted under applicable law, irrevocably and unconditionally waives any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim
that any such suit, action or proceeding has been brought in any inconvenient forum. Each of the parties hereto agrees that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon it and
may be enforced in any other courts to whose jurisdiction it is or may be subject, by suit upon judgment. YOU AND WE IRREVOCABLY AGREE TO WAIVE TRIAL BY JURY IN ANY SUIT, ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM BROUGHT BY OR ON BEHALF OF ANY PARTY
RELATED TO OR ARISING OUT OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THIS COMMITMENT LETTER. 
  

 7 

 You agree that you will not disclose, directly or indirectly, this Commitment Letter, the Term Sheet, the
Fee Letter, the contents of any of the foregoing or our activities pursuant hereto or thereto to any person without our prior written approval, except that (a) you may disclose this Commitment Letter, the Term Sheet, the Fee Letter and the
contents hereof and thereof (i) to your officers, directors, employees, attorneys, accountants and advisors on a confidential basis (except that neither the Fee Letter nor the contents thereof may be disclosed to your financial advisors, it
being understood and agreed that you may disclose on an aggregate basis the amount of the fees and expenses of the Transactions), (ii) as required by applicable law, rule, regulation or compulsory legal process (in which case you agree, to the
fullest extent permitted under applicable law, to inform us promptly thereof) or (iii) in connection with the exercise of any remedies hereunder or any related document or any suit, action or proceeding relating to this Commitment Letter, the
Term Sheet, the Fee Letter or any related document or the enforcement of rights hereunder or thereunder and (b) after your execution and delivery of this Commitment Letter and the Fee Letter, you may disclose this Commitment Letter, the
Term Sheet and the contents hereof and thereof (but not the Fee Letter or the contents thereof except as permitted pursuant to clause (a)(ii) above) in one or more filings with the Securities and Exchange Commission and other regulatory bodies
(including relevant stock exchanges) having jurisdiction over you and you may refer to this Commitment Letter and the principal terms of JPMCB’s commitments hereunder (but not the Fee Letter or the terms thereof) in one or more press releases;
provided that you will provide us with a copy of any press release referring to any of us reasonably in advance of its release. 
 We
and our affiliates will use all confidential information provided to us or such affiliates by or on behalf of you hereunder solely for the purpose of providing the services which are the subject of this Commitment Letter, for purposes of the
protection and enforcement of our rights and in connection with other credit relationships with you, your affiliates and your former affiliates, and shall treat confidentially all such information; provided that nothing herein shall prevent
such person from disclosing any such information (a) as required by applicable law or compulsory legal process (in which case we agree, to the extent permitted by law, to inform you promptly thereof), (b) upon the request or demand of any
regulatory authority having jurisdiction over such person of any of its affiliates, (c) to the extent that such information becomes publicly available other than by reason of improper disclosure by such person or any of its affiliates,
(d) to the extent that such information is received by such person from a third party that is not to such person’s knowledge subject to confidentiality obligations with respect to such information, (e) to the extent that such
information is independently developed by such person, (f) to such person’s affiliates and to its and their employees, legal counsel, independent auditors and other experts or agents who need to know such information in connection with the
transactions contemplated hereby and are informed of the confidential nature of such information or (g) to potential and prospective Lenders and any direct or indirect contractual counterparties to any swap or derivative transaction relating to
transactions contemplated hereby, in each case, who have been advised of the confidential nature of the information. 
  

 8 

 We hereby notify you that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L.
107-56 (signed into law October 26, 2001) (the “Patriot Act”)), each of us and each of the other Lenders may be required to obtain, verify and record information that identifies you and your subsidiaries, which information may
include your and their names and addresses and other information that will allow each of us and the other Lenders to identify you and your subsidiaries in accordance with the Patriot Act. This notice is given in accordance with the requirements of
the Patriot Act and is effective for each of us and the other Lenders. 
 The compensation, reimbursement, indemnification, governing law,
jurisdiction, venue and confidentiality provisions contained herein, in the Fee Letter and in the Term Sheet shall remain in full force and effect regardless of whether the Loan Documentation shall be executed and delivered and notwithstanding the
termination of this Commitment Letter or JPMCB’s commitments hereunder; provided that your obligations under this Commitment Letter (other than your obligations with respect to syndication and with respect to confidentiality of the Fee
Letter and the contents thereof) and our confidentiality obligations hereunder shall automatically terminate and be superseded by the provisions of the Loan Documentation upon the initial funding thereunder, and you and we shall automatically be
released from all liability in connection therewith at such time. You may terminate this Commitment Letter and our commitments hereunder at any time subject to the provisions of the preceding sentence. 
 Please indicate your acceptance of the terms hereof and of the Term Sheet and the Fee Letter by returning to JPMorgan executed counterparts of this
Commitment Letter and the Fee Letter not later than 5:00 p.m., New York City time, on May 31, 2007, failing which this Commitment Letter and JPMCB’s commitments and the Arranger’s agreements hereunder will terminate. If the
closing of the Facilities has not occurred on or before September 30, 2007, this Commitment Letter and JPMCB’s commitments and the Arranger’s agreements hereunder shall automatically terminate unless we and you shall agree to an
extension. If you elect to deliver this Commitment Letter by facsimile or other electronic imaging means, please arrange for the executed original to follow by next day courier. 
  

 9 

 We are pleased to have been given the opportunity to assist you in connection with this important
financing. 
  

					
	Very truly yours,	 	
		
	JPMORGAN CHASE BANK, N.A.,	 	
			
	by	 	 /s/ Dawn L. LeeLum
	 	
	Name:	 	Dawn L. LeeLum	 	
	Title:	 	Executive Director	 	

  

					
	J.P. MORGAN SECURITIES INC.,	 	
			
	by	 	 /s/ William Carney
	 	
	Name:	 	William Carney	 	
	Title:	 	Vice President	 	

			
	Accepted and agreed as of the date first above written:
	
	PHARMERICA, INC.,
		
	by	 	 /s/ Jack F. Quinn

	Name:	 	Jack F. Quinn
	Title:	 	Vice President and Treasurer

  

			
	KINDRED PHARMACY SERVICES, INC.,
		
	by	 	 /s/ Richard A. Lechleiter

	Name:	 	Richard A. Lechleiter
	Title:	 	Executive Vice President and Chief Financial Officer

  

			
	SAFARI HOLDING CORPORATION,
		
	by	 	 /s/ Gregory Weishar

	Name:	 	Gregory Weishar
	Title:	 	Chief Executive Officer

 EXHIBIT A 
 Project Safari 
 $375,000,000 Senior Secured Credit Facilities 
 Summary of Principal Terms and Conditions 
 Capitalized terms used but not defined in this Summary of Principal Terms and Conditions shall have the meanings set forth in Annex II hereto. 
 PART I 
 SPINCO LOANS 
  

			
	Borrowers:	  	PharMerica, Inc., a Delaware corporation (“PharMerica LTC”) and Kindred Pharmacy Services, Inc., a Delaware corporation (“KPS” and, together with PharMerica
LTC, the “Spinco Borrowers”). The obligations of each Spinco Borrower shall be several and not joint.
		
	Transactions:	  	As set forth in the Description of the Transactions attached as Annex II hereto.
		
	Spinco Loans:	  	 Daylight loans (the “Spinco Loans”) made pro rata by the lenders under the Term Facility:
  
 (A)   to PharMerica LTC in an aggregate
principal amount equal to the amount of the Spinco Distribution to be made by PharMerica LTC; and
  
 (B)   to KPS in an aggregate principal amount equal to the amount of the Spinco Distribution to be made by
KPS;
  
 provided that the aggregate principal amount of the Spinco Loans made to
PharMerica LTC and KPS shall not taken together exceed $250,000,000.

		
	Purpose:	  	The proceeds of the Spinco Loans will be used by each Spinco Borrower on the date on which the Spin-offs and Mergers are consummated (such date, the “Closing Date”) to make the
Spinco Distributions described on Annex II hereto.
		
	Availability:	  	The full amount of the Spinco Loans must be borrowed in a single drawing on the Closing Date.
		
	Interest Rates and Fees:	  	Same as under the Term Facility.

			
	Maturity:	  	The Spinco Loans will mature on the Closing Date and will be repaid by Newco with a portion of the proceeds of the Term Facility immediately following the consummation of the Spin-off
Transactions.
		
	Voluntary Prepayment:	  	Voluntary prepayment of the Spinco Loans will be permitted without penalty or premium.
		
	Conditions Precedent:	  	Same as for the Permanent Facilities, other than the consummation of the Spin-off Transactions.
		
	Governing Law and Forum:	  	New York.

 PART II 
 PERMANENT FACILITIES 
  

			
	Borrower:	  	Safari Holding Corporation, a Delaware corporation to be renamed PharMerica Corporation on the Closing Date (“Newco”).
		
	Transactions:	  	As set forth in the Description of the Transactions attached as Annex II hereto.
		
	Sole Lead Arranger and Sole Bookrunner:	  	J.P. Morgan Securities Inc. will act as sole lead arranger and sole bookrunner for each of the Permanent Facilities (in such capacities, the “Arranger”).
		
	Administrative Agent and Collateral Agent:	  	JPMorgan Chase Bank, N.A. (“JPMCB”) will act as sole administrative agent and collateral agent for each of the Permanent Facilities (in such capacities, the
“Agent”).
		
	Syndication Agent:	  	To be determined.
		
	Documentation Agent:	  	To be determined.

  

 2 

			
	Lenders:	  	A syndicate of banks, financial institutions and other entities, including JPMCB, identified and arranged by the Arranger and reasonably acceptable to the Borrower (collectively, the
“Lenders”).
		
	Facilities:	  	 (A)   A senior secured revolving credit facility in an aggregate principal amount of $100,000,000 (the “Revolving
Facility”). In the event that sufficient commitments are available, Newco may elect to increase the Revolving Facility to $150,000,000.

		
		  	 (B)   A senior secured term loan facility in an aggregate principal amount of $275,000,000 (the “Term
Facility” and, together with the Revolving Facility, the “Permanent Facilities”).

		
	Letters of Credit:	  	Up to $25,000,000 of the Revolving Facility will be available to Newco for the issuance of U.S. Dollar denominated letters of credit (the “Letters of Credit”) by one or more
Lenders or their affiliates (in such capacity, the “Issuing Banks”). Each Letter of Credit shall expire after the earlier of (a) 12 months after its date of issuance and (b) the fifth business day prior to the final maturity of the
Revolving Facility; provided that any Letter of Credit with a one-year tenor may provide for renewal thereof under customary “evergreen” provisions for additional one-year periods (which in no event shall extend beyond the date
referred to in clause (b) above).
		
		  	Drawings under any Letter of Credit shall be reimbursed by Newco on the same (or, if the Borrower receives notice of such drawing later than a time to be agreed, the next) business day (and
may be reimbursed with the proceeds of loans under the Revolving Facility). To the extent Newco does not so reimburse the applicable Issuing Bank, the Lenders participating in the Revolving Facility will be irrevocably and unconditionally obligated
to reimburse such Issuing Bank on a pro rata basis in accordance with their commitments under the Revolving Facility.

  

 3 

			
		  	The issuance of Letters of Credit shall be subject to the customary procedures of the applicable Issuing Bank.
		
	Swingline Loans:	  	JPMCB (in such capacity, the “Swingline Lender”) will make available to Newco a swingline facility under which Newco may make short-term borrowings (the “Swingline
Loans”) in an aggregate principal amount not in excess of $10,000,000. Except for purposes of calculating the Commitment Fee described in Annex I hereto, outstanding Swingline Loans will reduce availability under the Revolving
Facility on a dollar-for-dollar basis.
		
		  	Upon notice from the Swingline Lender, Lenders participating in the Revolving Facility will be irrevocably and unconditionally obligated to purchase participations in outstanding Swingline Loans
pro rata in accordance with their commitments under the Revolving Facility.
		
	Purpose:	  	 (A)   On the Closing Date, the proceeds of the loans under the Term Facility will be used (i) to refinance in full the Spinco
Loans and (ii) to pay fees and expenses incurred in connection with the transactions described in Annex II.

		
		  	 (B)   The proceeds of loans under the Revolving Facility will be used by Newco for working capital and other general corporate
purposes

		
		  	 (C)   Letters of Credit will be used by Newco for general corporate purposes.

		
	Availability:	  	 (A)   The entire aggregate principal amount of the Term Facility must be drawn in a single drawing on the Closing Date. Amounts
repaid under the Term Facility may not be reborrowed.

		
		  	 (B)   Loans and Letters of Credit under the Revolving Facility will be available at any time on or after the Closing Date and
prior to the final maturity or earlier termination of the Revolving Facility (and in the case of ABR

  

 4 

			
		  	 borrowings under the Revolving Facility will be available on a same day basis). No more than $20,000,000 may be borrowed under the Revolving Facility on the
Closing Date. Amounts repaid under the Revolving Facility may be reborrowed, subject to satisfaction of the borrowing conditions.

		
	Maturity:	  	 (A)   The Term Facility will mature on the date that is five years after the Closing Date. There will be no amortization
under the Term Facility.

		
		  	 (A)   The Revolving Facility will mature, and the commitments thereunder will terminate, on the fifth anniversary of the
Closing Date.

		
	Interest Rates and Fees:	  	As set forth on Annex I hereto.
		
	Increase of Revolving Facility:	  	The Loan Documentation (as defined below) will permit Newco, subject to satisfaction of customary conditions, to obtain additional commitments under the Revolving Facility in an aggregate
principal amount of up to $50,000,000 from Lenders or other financial institutions reasonably acceptable to the Agent that are willing, in their sole discretion, to provide such additional commitments.
		
	Guarantees:	  	All obligations of Newco under each of the Permanent Facilities and all obligations under any interest rate, currency, commodity or other hedging arrangements or under any cash management or
purchasing card arrangements entered into by Newco with any Lender (or affiliates thereof) (collectively, the “Obligations”) will be unconditionally guaranteed (the “Guarantees”), on a joint and several basis, by
each existing and each subsequently acquired or organized wholly owned subsidiary of Newco other than subsidiaries that are controlled foreign corporations (“CFCs”) for US tax purposes (collectively, the “Subsidiary Loan
Parties”). Newco and the Subsidiary Loan Parties are collectively referred to as the “Loan Parties”.
		
	Security:	  	The Obligations and the Guarantees will be secured by first-priority pledges of, security interests in, and mortgages on, (a) all the equity interests in each

  

 5 

			
		 	existing and each subsequently acquired or organized Subsidiary Loan Party and in each existing and each subsequently acquired or organized direct subsidiary of any Loan Party (which pledge, in
the case of equity interests in any first-tier CFC shall be limited to 100% of the non-voting equity interests and 66% of the voting equity interests in such subsidiary), (b) substantially all the tangible and intangible assets and properties of
each Loan Party (including but not limited to cash, cash equivalents, deposit accounts, securities accounts, accounts receivable, instruments, chattel paper, documents, investment property, intercompany notes, inventory, general intangibles,
intellectual property and licenses, letter of credit rights, commercial tort claims, equipment and real property interests) and (c) all proceeds of the foregoing (collectively, the “Collateral”); provided that (i) security
interests shall not be provided in (A) motor vehicles, (B) deposit accounts, (C) immaterial fee interests in real property, (D) real property leases, (E) letters of credit and letter of credit rights not constituting supporting obligations, (F)
intellectual property to the extent perfection of a security interest thereon requires any filing to be made outside the United States, (G) money, (H) contracts, licenses, leases, permits and other property subject to enforceable provisions (after
giving effect to the applicable provisions of the Uniform Commercial Code) that would be violated by the granting of a security interest thereon and (ii) the Loan Parties shall not be required to (A) enter into control agreements or otherwise
provide control with respect to any securities accounts, (B) except in connection with the mortgage of material fee interests in real property, make any fixture filings or any other filings in any real estate recording office, or (C) deliver any
security certificates, instruments or chattel paper other than (x) certificates evidencing equity interests in subsidiaries constituting certificated securities or (y) intercompany indebtedness in excess of an amount to be agreed.
		
		 	All the above-described pledges, security interests

  

 6 

			
		  	and mortgages shall be created on customary terms, and pursuant to customary documentation, reasonably satisfactory to the Agent. On the Closing Date, such pledges, security interests and
mortgages shall have been perfected (or arrangements for the perfection thereof on the Closing Date reasonably satisfactory to the Agent shall have been made) and the Agent shall have received reasonably satisfactory evidence as to the
enforceability, perfection and priority thereof. None of the Collateral shall be subject to any other liens, except as permitted by the Loan Documentation.
		
		  	Notwithstanding the foregoing, the Agent may agree to exclude particular assets from the Collateral where it determines that the costs of including such assets would be excessive in relation
to the benefits afforded to the Lenders.
		
	Mandatory Prepayments:	  	Loans under the Term Facility, but not loans or letters of credit under the Revolving Facility will be required to be prepaid with (a) 100% of the net cash proceeds received by Newco or any
of its subsidiaries from any sale, transfer or other disposition of assets or properties of Newco or any of its subsidiaries and insurance proceeds or condemnation awards in respect of any such assets or properties, in each case for any such
transaction or series of related transactions in an amount exceeding an amount to be agreed (other than sales of inventory in the ordinary course of business, certain contemplated dispositions to be specified in the Loan Documentation and other
limited exceptions to be agreed upon and subject to a right, without limitation as to amount, to reinvest any such proceeds within 365 days of receipt (or, if a binding commitment to so reinvest such proceeds is entered into during such 365-day
period, within 180 days after the end of such 365-day period), and (b) 100% of the net cash proceeds of incurrences of indebtedness by Newco or any of its subsidiaries (other than Indebtedness permitted under the Loan Documentation except to the
extent a prepayment is required as a condition to any such incurrence).

  

 7 

			
	Optional Prepayments and Commitment Reductions:	  	Optional prepayments, in whole or in part, of loans under any of the Permanent Facilities and optional permanent reductions, in whole or in part, of commitments under the Revolving Facility
will be permitted at any time in minimum principal amounts to be agreed upon, without premium or penalty; provided that, in the case of reductions of commitments under the Revolving Facility, any outstanding loans under the Revolving Facility
that, together with letter of credit exposures and Swingline Loans, would exceed the reduced commitments must be prepaid and, in the case of prepayment of an Adjusted LIBO Rate loan other than at the end of the applicable interest period, the
redeployment costs must be reimbursed.
		
	Documentation:	  	The Permanent Facilities will be documented pursuant to a credit agreement and other loan, security and guarantee documentation incorporating the terms contained herein and other customary
terms and provisions usual for facilities and transactions of this type that shall be mutually agreed (collectively and, together with the definitive documentation in respect of the Spinco Loans, the “Loan
Documentation”).
		
	Representations and Warranties:	  	Representations and warranties (to be applicable to Newco and its subsidiaries) shall consist of the following: organization and powers; authorization and enforceability; material approvals,
consents and filings; absence of conflicts; material accuracy of financial statements; absence of material adverse change; title to material properties; intellectual property rights; absence of pending or threatened litigation or investigations;
material regulatory and environmental matters; material compliance with laws (including ERISA, margin regulations and environmental laws) and, as of the Closing Date, no material adverse effect in respect of material agreements; absence of defaults;
inapplicability of the Investment Company Act; payment of taxes; ERISA and employment benefit matters; accuracy of disclosure; corporate structure and subsidiaries at the Closing Date; insurance; Federal Reserve regulations; solvency at the Closing
Date; and validity, perfection and priority of security interests in the Collateral.

  

 8 

			
	Conditions Precedent to Initial Extension of Credit:	  	 The availability of the Permanent Facilities will be conditioned upon the satisfaction of the following conditions precedent: execution and
delivery by the Loan Parties and the Agent of the Loan Documentation, delivery of legal opinions from counsel to the Spinco Borrowers and Newco, evidence of authority and officers’ certificates, delivery of customary documents and certificates
relating to organization, existence and good standing of each Loan Party, the execution and delivery of security documents, which shall be in full force and effect, and delivery of a completed perfection certificate, evidence of insurance,
certification of solvency (after giving effect to the transactions contemplated hereby), and, to the extent invoiced, payment or reimbursement of the Agent’s reasonable out-of-pocket expenses required to be paid pursuant to the Loan
Documentation, including the reasonable fees, charge and disbursements of counsel for the Agent.
  
 Under the Loan Documentation, the availability of the Permanent Facilities will also be subject to the conditions precedent set forth in Annex III hereto.

		
	Conditions Precedent to Each Extension of Credit:	  	The making of each extension of credit (including the initial extension of credit) under the Permanent Facilities shall be conditioned upon (a) the accuracy of representations and warranties
in all material respects, (b) the absence of defaults or events of default at the time of, or after giving effect to the making of, such extension of credit and (c) the delivery of a borrowing notice.
		
	Affirmative Covenants:	  	Affirmative covenants (to be applicable to Newco and its subsidiaries and with exceptions and materiality and other qualifications to be agreed), shall consist of: delivery of financial
statements, annual budgets and other information; delivery of notices of default, litigation, ERISA events and other material events; information regarding Collateral; maintenance of existence and rights and licenses; conduct of business; payment
and performance of obligations; maintenance of

  

 9 

			
		  	properties; maintenance of insurance; maintenance of books and records; inspection and audit rights; compliance with laws and with contractual obligations; use of proceeds; and further
assurances with respect to Collateral, Guarantees and new subsidiaries.
		
	Negative Covenants:	  	Negative covenants (to be applicable to Newco and its subsidiaries and with exceptions, baskets and other qualifications to be agreed) shall consist of: limitations on indebtedness and
preferred equity interests; limitations on liens; limitations on fundamental changes; limitations on investments, loans, advances, guarantees and acquisitions (it being understood that the limitations on investments in non-wholly owned subsidiaries
will permit working capital advances to be made to such subsidiaries in an aggregate amount at any time outstanding not to exceed an available amount basket to be agreed); limitations on asset dispositions (including on dispositions resulting in
subsidiaries becoming non-wholly owned); limitations on sale-leaseback transactions; limitations on hedging agreements; limitations on dividends and distributions on, and redemptions and repurchases of, equity interests and other similar payments;
limitation on prepayments, redemptions and repurchases of certain specified debt to be agreed; limitations on transactions with affiliates; limitations on restrictive agreements affecting subsidiaries; prohibition of changes in fiscal year; and
limitations on lines of business.
		
	Financial Covenants:	  	The Loan Documentation will contain the following financial covenants (with definitions and levels to be agreed upon): (a) maximum ratio of total indebtedness to consolidated EBITDA for the
period of four consecutive fiscal quarters most recently ended and (b) (other than at any time when either (A) the leverage ratio described in clause (a) is less than 2.0 to 1.0 or (B) both S&P and Moody’s shall have in effect for Newco
corporate credit ratings that are investment grade) minimum ratio of (i) consolidated EBITDAR minus maintenance capital expenditures to (ii) consolidated interest expense plus rents plus scheduled amortization for any period of four consecutive
fiscal quarters.

  

 10 

			
	Events of Default:	  	Events of default (to be applicable to Newco and its subsidiaries and to be subject to exceptions, baskets and materiality and other qualifications to be agreed) shall consist of: nonpayment
of principal, interest or other amounts; inaccuracy of representations and warranties; breach of covenants; cross default and cross acceleration to material debt obligations; certain bankruptcy and insolvency events in respect of Newco and its
subsidiaries other than immaterial subsidiaries; material judgments; ERISA events; actual or asserted invalidity of security documents or Guarantees; failure of Lenders’ liens to be perfected on Collateral; failure of Loan Documentation to be
in full force and effect; and Change in Control (to be defined).
		
	Voting:	  	Amendments and waivers of the Loan Documentation relating to the Permanent Facilities will require the approval of Lenders holding more than 50% of the sum of the aggregate amount of the
loans, letter of credit exposures and unused commitments under the Permanent Facilities, except that (a) the consent of each adversely affected Lender shall be required with respect to (i) increases in such Lender’s commitments, (ii) reductions
of such Lender’s principal, interest or fees, (iii) extensions of final maturity of such Lender’s loans or commitments or dates on which payments to such Lender are due, (b) the consent of each Lender will be required with respect to (i)
modifications to any of the voting percentages included in such Loan Documentation, (ii) modifications of the pro rata provisions included in such Loan Documentation, (iii) releases of all or substantially all of the Collateral and (iv)
releases of all or substantially all of the Guarantees, (c) (i) the consent of a requisite percentage in interest of any class of Lenders will be required for amendments and waivers that by their terms adversely affect such class of Lenders
differently from the Lenders of any other class and (ii) only the consent of the requisite percentage in interest of any class or classes of Lenders (and not of any other

  

 11 

			
		  	class or classes of Lenders) will be required for amendments and waivers that, together with related amendments and waivers, by their terms adversely affect only the rights of such class or
classes (and not of such other class or classes) and (d) the consent of the Agent, the applicable Issuing Bank and the Swingline Lender will be required to amend, modify or otherwise affect the rights and duties of the Agent, such Issuing Bank or
the Swingline Lender, as the case may be.
		
	Cost and Yield Protection; Withholding Taxes:	  	Usual for facilities and transactions of this type.
		
	Assignments and Participations:	  	Lenders will be permitted to assign loans and commitments with the consent, not to be unreasonably withheld, of (a) Newco (unless (i) an event of default has occurred and is continuing or
(ii) such assignment is an assignment (A) under the Revolving Facility to a Lender with a commitment under the Revolving Facility immediately prior to such assignment or (B) under the Term Facility to a Lender, an affiliate of a Lender or an
approved fund), and (b) the Agent (unless such assignment is an assignment (i) under the Revolving Facility to a Lender with a commitment under the Revolving Facility immediately prior to such assignment or (ii) under the Term Facility to a Lender,
an affiliate of a Lender or an approved fund), and (c), in the case of assignments under the Revolving Facility, the Issuing Bank. Each assignment (except an assignment of the entire remaining principal amount of the assigning Lender’s loans or
commitments under the applicable Facility or an assignment to another Lender, an affiliate of a Lender or an approved fund) will be in a minimum amount of (a) $5,000,000 in respect of loans and commitments under the Revolving Facility and (b)
$5,000,000 in respect of loans under the Term Facility. The Agent will receive a processing and recordation fee of $3,500, payable by the assignor and/or the assignee, with each assignment. Assignments will be by novation and will not be required to
be pro rata among the Facilities.
		
		  	The Lenders will be permitted to participate loans

  

 12 

			
		  	and commitments without restriction. Voting rights of participants shall be limited to customary matters.
		
	Expenses and Indemnification:	  	Newco will pay (a) all reasonable out-of-pocket expenses (including reasonable fees, disbursements and other charges of external counsel) of the Arranger and the Agent associated with the
structuring, arrangement and syndication of the Facilities and with the preparation, execution, delivery, administration, waiver or modification of the Loan Documentation and (b) all reasonable out-of-pocket expenses (including reasonable fees,
disbursements and other charges of counsel) of the Arranger, the Agent and the Lenders (which in the case of each of them may include external or internal counsel but not both) in connection with the enforcement of the Loan Documentation. In
addition, all documentary taxes associated with the Facilities will be paid by Newco.
		
		  	Newco will indemnify the Arranger, the Agent, the Lenders, their affiliates and their and their affiliates’ officers, directors, employees, agents, advisors and controlling persons and
hold them harmless from and against all claims, damages, losses, liabilities and expenses (including reasonable fees, disbursements and other charges of counsel) of any such indemnified person arising out of or relating to the Loan Documentation,
the Facilities, the use of proceeds thereof, the transactions contemplated hereby or any related claim, litigation or other proceeding (regardless of whether based in contract, tort or any other theory, whether brought by Newco, its affiliates or
any other person or whether any indemnified person is a party thereto); provided that no indemnified person will be indemnified for claims, damages, losses, liabilities or related expenses to the extent they are found by a final,
non-appealable judgment of a court of competent jurisdiction to have resulted from the gross negligence, bad faith or willful misconduct of such indemnified person or from the breach by such indemnified party of its agreements under the Loan
Documents.

  

 13 

			
	Governing Law and Forum:	  	New York.
		
	Counsel to Agent and Arranger:	  	Cravath, Swaine & Moore LLP.

  

 14 

 ANNEX I 
 TO EXHIBIT A 
  

			
	Interest Rates:	  	The interest rates under the Permanent Facilities will be as follows:
		
		  	Revolving Facility
		
		  	Newco may elect that the loans under the Revolving Facility bear interest at a rate per annum equal to (a) ABR plus the Applicable Margin for ABR loans or (b) the Adjusted LIBO Rate
plus the Applicable Margin for Adjusted LIBO Rate loans.
		
		  	Term Facility
		
		  	Newco may elect that the loans under the Term Facility bear interest at a rate per annum equal to (a) ABR plus the Applicable Margin for ABR loans or (b) the Adjusted LIBO Rate
plus the Applicable Margin for Adjusted LIBO Rate loans.
		
		  	As used herein:
		
		  	“ABR” means the higher of (a) the rate of interest publicly announced by JPMCB as its prime rate in effect at its principal office in New York City (the “Prime
Rate”) and (b) the Federal funds effective rate from time to time plus 0.50%.
		
		  	“Adjusted LIBO Rate” means the London interbank offered rate, adjusted for statutory reserve requirements.
		
		  	The “Applicable Margin” will in each case be the spread specified in the table appearing at the end of this Annex I, based on the Leverage Ratio (to be defined) at the
time of determination.
		
	Interest Periods:	  	Newco may elect interest periods of one, two, three, six or, if available from all applicable Lenders, nine or twelve months for Adjusted LIBO Rate loans.
		
	Interest Payment Dates:	  	Interest will be payable on loans bearing interest based on the Adjusted LIBO Rate in arrears on the last day of each relevant interest period and, in the case of any interest period longer than
three months, on each successive date three months after the first day of such interest period, upon repayment of the relevant loan and at final maturity.

			
		
		  	Interest will be payable on loans bearing interest based on ABR in arrears quarterly, at final maturity and, in the case of ABR loans under the Term Facility and Swingline Loans, upon repayment
of the relevant loan.
		
	Default Rate:	  	The default rate on overdue amounts will be the applicable interest rate on such amount plus 2.00% per annum.
		
	Commitment Fee:	  	A Commitment Fee will accrue and be payable on the daily unused commitments under the Revolving Facility, commencing to accrue on the Closing Date and payable in arrears at the end of each
quarter and upon termination of the Revolving Facility. The per annum rate at which the Commitment Fee will accrue at any time will be the Commitment Fee specified in the table appearing at the end of this Annex I, based on the Leverage Ratio
(to be defined) at such time. For the purpose of calculating the Commitment Fees, outstanding Swingline Loans will be deemed not to utilize the commitments under the Revolving Facility.
		
		  	The Commitment Fee shall be distributed to Lenders participating in the Revolving Facility pro rata in accordance with their commitments thereunder.
		
	Letter of Credit Fees:	  	A Letter of Credit Fee will accrue on the daily aggregate face amount of outstanding Letters of Credit, payable in arrears at the end of each quarter and upon termination of the Revolving
Facility. The per annum rate at which the Letter of Credit Fee will accrue will be the Applicable Margin for LIBOR loans under the Revolving Facility.
		
		  	The Letter of Credit Fee shall be distributed to Lenders participating in the Revolving Facility pro rata in accordance with their commitments thereunder.
		
		  	In addition, Newco shall pay to the applicable Issuing Bank, for its own account, (a) a fronting fee in an amount to be agreed upon on the daily aggregate face amount of outstanding Letters
of Credit, payable in

  

 2 

			
		  	arrears at the end of each quarter and upon termination of the Revolving Facility and (b) such Issuing Bank’s customary issuance and administration fees.
		
	Interest Rate and Fee Basis:	  	All interest and fees will be calculated on the basis of actual days elapsed in a year of 360 days (or 365 or 366 days, as the case may be, in the case of ABR loans based on the Prime
Rate).

  

							
	 Total Leverage Ratio
	  	Commitment Fee
(bps)	  	LIBOR Spread
(bps)	  	ABR Spread
(bps)
	           >4.0x
	  	25.0	  	175.0	  	75.0
	 > 3.5x but £ 4.0x
	  	25.0	  	150.0	  	50.0
	 > 3.0x but £ 3.5x
	  	20.0	  	125.0	  	25.0
	 > 2.0x but £ 3.0x
	  	17.5	  	100.0	  	0
	 > 1.0x but £ 2.0x
	  	15.0	  	75.0	  	0
	           £1.0x
	  	12.5	  	62.5	  	0

  

 3 

 ANNEX II 
 TO EXHIBIT A 
 Project Safari 
 Description of the Transactions 
 This Transaction Description outlines the transactions you have
advised us that you intend to consummate in connection with the Spin-offs and Mergers described below. The date on which the Spin-offs and Mergers are consummated is referred to as the “Closing Date”. Capitalized terms used but not
defined in this Annex II shall have the meanings set forth in the Summary of Principal Terms and Conditions to which this Annex II is attached. 
 The transactions set forth below will be consummated on the Closing Date pursuant to the Master Transaction Agreement dated as of October 25, 2006 (such agreement, together with the related definitive documentation, the
“Transaction Agreement”), by and among AmerisourceBergen Corporation, a Delaware corporation (“AmerisourceBergen”), PharMerica, Inc., a Delaware corporation and wholly owned subsidiary of AmerisourceBergen
(“PharMerica LTC”), Kindred Healthcare, Inc., a Delaware corporation (“Kindred”), Kindred Healthcare Operating, Inc., a Delaware corporation and wholly owned subsidiary of Kindred (“KHO”), Kindred
Pharmacy Services, Inc., a Delaware corporation and wholly owned subsidiary of KHO (“KPS”), Safari Holding Corporation, a Delaware corporation (“Newco” and, together with AmerisourceBergen and Kindred,
“you”), Hippo Merger Corporation, a Delaware corporation and wholly owned subsidiary of Newco (“Hippo Merger Sub”), and Rhino Merger Corporation, a Delaware corporation and wholly owned subsidiary of Newco
(“Rhino Merger Sub”). 
  

	 	(a)	(i) Pharmacy Corporation of America, a Delaware corporation and a wholly-owned subsidiary of PharMerica LTC, will transfer its wholly owned subsidiaries PMSI, Inc. and TMESYS,
Inc., which conduct AmerisourceBergen’s workers’ compensation services businesses, to AmerisourceBergen or a subsidiary of AmerisourceBergen that is not a subsidiary of PharMerica LTC, (ii) each of AmerisourceBergen, PharMerica LTC,
Kindred and KPS will take all actions necessary to cause AmerisourceBergen and Kindred, respectively, to own all of PharMerica LTC’s and KPS’s right, title and interest in all assets that are not owned, used or held for use primarily in
connection with the institutional pharmacy business of PharMerica LTC or KPS, respectively, and to assign and transfer to AmerisourceBergen and Kindred, respectively, all of PharMerica LTC’s and KPS’s liabilities not relating to its
institutional pharmacy business and (iii) each of AmerisourceBergen, PharMerica LTC, Kindred and KPS will take all actions necessary to cause PharMerica LTC and KPS, respectively, to own all of AmerisourceBergen’s and Kindred’s right,
title and interest in all assets used or held for use primarily in connection with the institutional pharmacy business that are not already owned by PharMerica LTC and KPS, and to assign and transfer to PharMerica LTC and KPS, respectively, all of
AmerisourceBergen’s and Kindred’s liabilities relating to its institutional pharmacy business that are not already liabilities of PharMerica LTC or KPS, respectively. 

	 	(b)	Using the proceeds of the Spinco Loans (as defined below), PharMerica LTC will make a cash distribution to AmerisourceBergen and KPS will make a cash distribution to KHO, which cash
distributions will total not more than $250,000,000 (together, the “Spinco Distributions”). 

  

	 	(c)	Immediately following the Spinco Distribution by KPS but prior to the spin-off of KPS described in clause (d), KHO will distribute all the outstanding shares of KPS to Kindred.

  

	 	(d)	Immediately following the transactions described in clauses (b) and (c), AmerisourceBergen will spin-off PharMerica LTC to the stockholders of AmerisourceBergen and Kindred
will spin-off KPS to the stockholders of Kindred (together, the “Spin-offs”). 

  

	 	(e)	Immediately following the Spin-offs, Hippo Merger Sub will merge with and into PharMerica LTC, with PharMerica LTC as the surviving corporation, and Rhino Merger Sub will merge with
and into KPS, with KPS as the surviving corporation (together, the “Mergers”), and each of PharMerica LTC and KPS will thereby become a wholly owned direct subsidiary of Newco. 

  

	 	(f)	Pursuant to the Mergers all outstanding shares of PharMerica LTC and KPS will be converted into shares of Newco and shares of Newco will, as consideration for the Mergers, be
distributed to the stockholders of AmerisourceBergen and Kindred. 

  

	 	(g)	Immediately following the foregoing transactions, Newco will use a portion of the proceeds of term loans under the Permanent Facilities (as defined below) to repay the Spinco Loans.

 The transactions set forth in clauses (a) through (f) above are referred to as the “Spin-off Transactions”).

  

 2 

 ANNEX III 
 TO EXHIBIT A 
 Project Safari 
 Conditions Precedent to Borrowings 
 on the Closing Date 
 The availability of each Permanent Facility, in addition to the conditions set forth in the Summary of Principal Terms and Conditions to which this Annex
III is attached, shall be subject to the satisfaction or waiver of the following conditions precedent. Capitalized terms used but not defined in this Annex III shall have the meanings set forth in such Summary or in Annex II thereto. 
  

	1.	The Spin-off Transactions shall have been, or shall substantially simultaneously be, consummated pursuant to the terms and conditions of the Transaction Agreement and related
agreements and consistent in all material respects with the information set forth in the Form S-4/S-1 filed with the Securities and Exchange Commission (the “SEC”) on May 24, 2007, including the pro forma financial information
contained therein (it being understood that while the Spin-off Transactions will be effected consistent in all material respects with the Form S-4/S-1 most recently filed with the SEC as of the Closing Date, satisfaction of the condition precedent
set forth in this paragraph 1 will be determined based upon material consistency with the Form S-4/S-1 filed on May 24, 2007, unless the Arranger shall agree to base such determination on a later filed Form S-4/S-1). There shall be no material
payments to AmerisourceBergen, Kindred or their affiliates in respect of the Spin-offs other than the Spinco Distributions and as otherwise required under the Transaction Agreement. No term or condition of the Transaction Agreement or any related
agreement shall have been waived, amended or otherwise modified in a manner material and adverse to the interests of the Lenders without the prior approval of the Arranger. The Arranger shall have received true and complete copies of the Transaction
Agreement, all other material agreements required to be delivered thereunder and all other material agreements delivered thereunder or in connection therewith. The terms of any agreements that are material to the interests of the Lenders entered
into in connection with the Spin-off Transactions shall not be inconsistent in any material respect with the terms of the Commitment Letter, the exhibits thereto, the Transaction Agreement and, if applicable, the form of such agreement filed with
the SEC on or prior to May 24, 2007. 

  

	2.	All pre-existing indebtedness and guarantees (subject to limited exceptions to be agreed upon) of Newco, PharMerica LTC and KPS and their respective subsidiaries shall have been
repaid or repurchased in full, all commitments relating thereto shall have been terminated, and all liens or security interests related thereto shall have been terminated or released, in each case on terms reasonably satisfactory to the Arranger,
and Newco, PharMerica LTC and KPS and their respective subsidiaries shall have outstanding no indebtedness or preferred equity interests other than (A) the loans and other extensions of credit under the Facilities and (B) other limited
indebtedness (including capital leases and purchase money debt in an aggregate amount up to $10,000,000) to be agreed upon. 

	3.	The Lenders shall have received copies of and be reasonably satisfied with the form and substance of each of (i) the solvency opinions of American Appraisal Associates and
Houlihan Lokey Howard & Zukin, delivered to the Boards of Directors of AmerisourceBergen and Kindred, respectively, and (ii) the opinions of counsel delivered to AmerisourceBergen and Kindred as to the tax-free nature of the Spin-offs.

  

	4.	The Arranger shall have received unaudited financial statements of PharMerica LTC and KPS for each fiscal quarter ended after March 31, 2007, but at least 45 days prior to
the Closing Date, all meeting the requirements of Regulation S-X for Form S-1 registration statements and all such financial statements shall be satisfactory in form and substance to the Arranger. 

  

	5.	The Arranger shall have received a pro forma consolidated balance sheet of Newco as of the date of the most recent consolidated balance sheet delivered pursuant to the
preceding paragraph and a pro forma statement of operations for the most recent fiscal year, interim period (if available), in each case adjusted to give effect to the Spin-off Transactions, the other transactions related thereto and any other
transactions that would be required to be given pro forma effect by Regulation S-X and such other adjustments as are customary for similar financings or as otherwise agreed between you and the Arranger. 

  

	6.	The Arranger and the Lenders shall have received current projections (broken down by quarter for the first year and by year thereafter) for Newco and its subsidiaries after giving
effect to the Spin-off Transactions through the fifth anniversary of the Closing Date. 

  

	7.	All material governmental, shareholder and third-party approvals and consents necessary in connection with the Spin-offs, the Mergers and the transactions contemplated thereby and
otherwise referred to herein, and all governmental, shareholder and third-party approvals and consents required in connection with the Facilities and the guarantees and security interests in respect thereof that are material to the interests of the
Lenders, shall have been received and shall be in full force and effect, and all applicable waiting periods shall have expired without any action being taken by any applicable authority. 

  

	8.	There shall not exist any action, suit, investigation, litigation or proceeding pending or, to the knowledge of Newco, PharMerica LTC or KPS, threatened in any court or before any
arbitrator or governmental authority that (a) has had or could reasonably be expected to have a material adverse effect on Newco and its subsidiaries or on PharMerica LTC, KPS and their respective subsidiaries, taken as a whole, or any of the
transactions contemplated hereby, or (b) relates to the financing transactions contemplated hereby which could reasonably be expected to adversely affect the interests of the Lenders. 

  

 2 

	9.	All costs, fees, reasonable, documented, out-of-pocket expenses (including, without limitation, reasonable, documented, out-of-pocket fees and expenses of external counsel to the
Arranger and the Agent) and other compensation payable to JPMCB, the Arranger or the Lenders shall have been paid, in each case to the extent invoiced at least one business day prior to the Closing Date. 

  

 3Employment Agreement dated July 11,2007 between Michael Culotta and Safari

 Exhibit 10.12 
 EMPLOYMENT AGREEMENT 
 THIS AGREEMENT by and between Safari Holding Corporation, a Delaware corporation
(hereinafter the “Company”), and Michael Culotta (the “Executive”), is effective as of the first day of business operations of PharMerica Corporation (“Closing Date”); 
 WHEREAS, as of the Closing Date, the Company intends to engage in the institutions pharmacy business as PharMerica Corporation; 
 WHEREAS, the Board of Directors of the Company (the “Board”), upon the recommendation of the Compensation and Succession Planning Committee of
the Board (the “Committee”), has determined that it is in the best interests of the Company and its shareholders to employ the Executive, effective as of the Closing Date, as the Executive Vice President and Chief Financial Officer of the
Company, and the Executive desires to serve in that capacity, effective as of the date of this Agreement; 
 NOW, THEREFORE, IT IS HEREBY
AGREED AS FOLLOWS: 
 1. Employment Period. The Company shall employ the Executive, either directly or through a Subsidiary, and the Executive
shall serve the Company or any such Subsidiary, on the terms and conditions set forth in this Agreement, beginning on the Closing Date (the “Employment Date”) and until that employment ceases as provided below in Section 4 (the
“Employment Period”). 
 2. Position and Duties. 
 (a) During the Employment Period, the Executive shall be employed as the Executive Vice President and Chief Financial Officer of the Company, subject to such changes in title as may be proposed by the Board or the
Chief Executive Officer and consented to by the Executive. The Executive shall report to the Chief Executive Officer of the Company and shall perform such duties for the Company as are related typically to the office of Executive Vice President and
Chief Financial Officer, in the manner reasonably directed by the Chief Executive Officer of the Company, in his discretion. 
 (b) During
the Employment Period, but excluding any periods of vacation and absence due to intermittent illness to which the Executive is entitled, and any services on corporate, civic or charitable boards or committees, lectures, speaking engagements or
teaching engagements that are approved by the Executive’s direct supervisor and that do not significantly interfere with the performance of the Executive’s responsibilities to the Company or violating the provisions of Section 9, the
Executive shall devote his full time and attention during normal business hours to the business and affairs of the Company and the Executive shall use reasonable efforts to carry out all duties and responsibilities assigned to him faithfully and
efficiently. 
 3. Compensation. 
 (a) Base Salary. During the Employment Period, the Executive shall receive an annual base salary of $405,000, payable in accordance with the regular payroll practices of the Company. The Executive’s base salary shall be reviewed
annually by the Committee and/or the Chief Executive Officer of the Company, in accordance with the Company’s standard practices for executives generally, and may be increased, but not decreased, as determined by the Committee, in its sole
discretion, or by any person or persons to whom the Committee has delegated such authority. 
  

 1 

 (b) Annual Bonus and Incentive Plans; Other Benefits. During the Employment Period: (i) the
Executive shall be entitled to participate in any short-term and long-term incentive programs established and/or maintained by the Company for its senior level executives generally; (ii) the Executive shall be entitled to participate in all
incentive, savings and retirement plans, practices, policies and programs of the Company to at least the same extent as other senior executives of the Company; (iii) the Executive and/or the Executive’s family, as the case may be, shall be
eligible for participation in, and shall receive all benefits under, all welfare benefit plans, practices, policies and programs provided by the Company to at least the same extent as other senior executives of the Company; and (iv) the
Executive shall be entitled to, and the Company shall provide the Executive with 4 weeks of paid vacation during each calendar year pursuant to the Company’s vacation policy. 
 (c) Expenses. During the Employment Period, the Executive shall be entitled to receive advancement or prompt reimbursement for all reasonable expenses
incurred or anticipated to be incurred by the Executive in carrying out the Executive’s duties under this Agreement, provided that the Executive complies with the generally applicable policies, practices and procedures of the Company for
submission of expense reports, receipts, or similar documentation of such expenses. 
 4. Termination of Employment. 
 (a) Death or Disability. The Executive’s employment and the Employment Period shall terminate automatically upon the Executive’s death or long
term Disability during the Employment Period. “Disability” means a condition entitling the Executive to benefits under the Company’s Long Term Disability Plan, policy or arrangement. 
 (b) By the Company. The Company may terminate the Executive’s employment under this Agreement during the Employment Period for Cause or without
Cause. “Cause” means 
 (i) the continued failure by the Executive to substantially perform his duties as contemplated by this
Agreement (other than any such failure resulting from his incapacity due to physical or mental illness or injury or any such actual or anticipated failure after the issuance by the Executive of a Notice of Termination for Good Reason) over a period
of not less than thirty days after a demand for substantial performance is delivered to the Executive by the Board or by the Chief Executive Officer of the Company, which demand identifies the manner in which it is believed that the Executive has
not substantially performed his duties; 
 (ii) the willful misconduct of the Executive materially and demonstrably injurious to the Company
(including, without limitation, any breach by the Executive of Section 9 of this Agreement); provided that no act or failure to act on the Executive’s part will be considered willful if done, or omitted to be done, by him in good faith and
with reasonable belief that his action or omission was in the best interest of the Company; 
 (iii) the commission by or indictment of the
Executive for a misdemeanor, which, as determined in good faith by the Board, constitutes a crime of moral turpitude and gives rise to material harm to the Company or to any subsidiary or affiliate of the Company; 
 (iv) the commission by or indictment of the Executive for a felony (including, without limitation, any felony constituting a crime of moral turpitude);
or 
 (v) material breach by the Executive of the Executive’s obligations under this Agreement. 
  

 2 

 (c) By the Executive. The Executive may terminate employment under this Agreement for Good Reason or
without Good Reason. “Good Reason” means: 
 (i) any reduction in the Executive’s Base Salary, incentive bonus opportunity or
long-term incentive opportunity; or 
 (ii) material failure by the Company to comply with any provision of Sections 2 and 3 of this
Agreement, other than an isolated, insubstantial or inadvertent failure that is not taken in bad faith and is remedied by the Company within 30 days after receipt of written notice thereof from the Executive. 
 Notwithstanding the foregoing, “Good Reason” for purposes of Section 4(c)(i) shall
not include a reduction in Base Salary, incentive bonus or long-term incentive opportunity if such reduction is coincident with a reduction applicable to all members of the senior management team. A termination of employment by the Executive for
Good Reason shall be effectuated by giving the Company written notice (“Notice of Termination for Good Reason”) of the termination, setting forth in reasonable detail the specific conduct that constitutes Good Reason and the specific
provision(s) of this Agreement on which the Executive relies. Such Notice of Termination for Good Reason must be received by the Company no later than the 60th day after the event, or last in a series of events, that gives rise to Good Reason. The Company shall have 20 days to remedy the conduct set forth in the Notice of Termination for Good Reason. A
termination of employment by the Executive for Good Reason shall be effective on the 60th business day following the
date when the Notice of Termination for Good Reason is given, unless the conduct set forth in the notice is remedied by the Company within the 20-day period. A termination of the Executive’s employment by the Executive without Good Reason shall
be effected by giving the Company at least 30 days’ advance written notice of the termination. 
 (d) Date of Termination. The
“Date of Termination” means the date of the Executive’s death, the date of the Executive’s Disability, the date the termination of the Executive’s employment under this Agreement by the Company for Cause or without Cause or
by the Executive for Good Reason or without Good Reason, as the case may be, is effective. The Employment Period shall end on the Date of Termination. 
 5. Obligations of the Company upon Termination. 
 (a) By the Company Other Than for Cause; or By the
Executive for Good Reason. If, during the Employment Period, the Company terminates the Executive’s employment under this Agreement (other than for Cause) or the Executive terminates employment under this Agreement for Good Reason: 

(1) the Executive shall be entitled to (i) continued payment for eighteen (18) months after the Date of Termination of the
Executive’s current base salary (as in effect on the Date of Termination), and (ii) a bonus equal to the average of the annual bonuses earned by the Executive over the three complete years (or if less than three years, the average bonus
earned during such shorter period) preceding the Date of Termination (that is, not including the bonus year that includes the Date of Termination) to be paid on the first business day at the conclusion of the eighteen month period after the Date of
Termination; and 
 (2) for the eighteen (18) month period following the Date of Termination, the Executive will receive
waiver of the applicable premium otherwise payable for COBRA continuation coverage for the Executive, his spouse and eligible dependents (to the extent covered on the Date of Termination) for health, prescription, dental and vision benefits;
provided, 

  

 3 

 
however, that to the extent COBRA continuation coverage eligibility expires (unless such expiration is due to eligibility for other group health insurance or
Medicare) before the end of such eighteen month period, the Executive will receive payment, on an after-tax basis, of an amount equal to the premium the Company would have otherwise waived for COBRA coverage. The obligations of the Company to
provide benefits under this Section 5(a)(2) shall terminate on the date of occurrence of the first to occur of any of the following, if any of the following should occur prior to the end of the eighteen (18) month period: (i) the date
of commencement of eligibility of the Executive under the group health plan of any other employer or (ii) the date of commencement of eligibility of the Executive for Medicare benefits. 
 In addition, the Executive shall be entitled to receive executive level outplacement assistance under any outplacement assistance program then being maintained by the
Company in accordance with the terms of any such program. The Executive shall also become vested in any outstanding options, restricted stock or other equity incentive awards only to the extent provided for under the terms governing such equity
incentive award. The Company shall also pay, or cause to be paid, to the Executive, in a lump sum in cash within 30 days after the Date of Termination (or, in the case of the pro-rated Annual Bonus Amount, at the time such bonus would otherwise be
paid), the Executive’s accrued but unpaid cash compensation (the “Accrued Obligations”), which shall include but not be limited to, (W) the Executive’s base salary through the Date of Termination that has not yet been paid
(X) an amount representing a 100% target bonus for the Executive’s salary grade for the year of termination, multiplied by a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination,
and the denominator of which is 365 (the “Annual Bonus Amount”), (Y) any accrued but unpaid vacation pay, and (Z) similar unpaid items that have accrued and as to which the Executive has become entitled as of the Date of
Termination, including declared but unpaid bonuses and unreimbursed employee business expenses; provided, however, that the Company’s obligation to make any payments, or cause any payments to be made, under this paragraph (a) to the extent
any such payment shall not have accrued as of the day before the Date of Termination shall also be conditioned upon the Executive’s execution, and non-revocation, of a written release, substantially in the form attached hereto as Exhibit 1, of
any and all claims against the Company and all related parties with respect to all matters arising out of the Executive’s employment under this Agreement or the termination thereof (other than any entitlements under the terms of this Agreement
to indemnification or under any other plans or programs of the Company in which the Executive participated and under which the Executive has accrued and is due a benefit). 
 If any payment, compensation or other benefit provided to the Executive in connection with his employment termination is determined, in whole or in part, to constitute “nonqualified deferred compensation”
within the meaning of Section 409A of the Code and the Executive is a specified employee as defined in Section 409A(a)(2)(B)(i) and Income Tax Regulations under Section 409A, no part of such payments shall be paid before the day that
is six (6) months plus one (1) day after the Date of Termination (the “New Payment Date”). The aggregate of any payments that otherwise would have been paid to the Executive during the period between the termination date and the
New Payment Date shall be paid to the Executive, without interest, in a lump sum on such New Payment Date. Thereafter, any payments that remain outstanding as of the day immediately following the New Payment Date shall be paid without delay over the
time period originally scheduled, in accordance with the terms of this Agreement. 
 (b) Death or Disability. If the Executive’s
employment is terminated by reason of the Executive’s death or Disability during the Employment Period, the Company shall pay the Accrued Obligations to the Executive or the Executive’s estate or legal representative, as applicable, in a
lump sum in cash within 30 days after the Date of Termination. If the Executive’s employment is terminated by reason of the Executive’s death, the Executive shall also become vested in any outstanding options, 

  

 4 

 
restricted stock or other equity incentive awards. If the Executive’s employment is terminated by reason of the Executive’s death or Disability,
the Company shall have no further obligations under this Agreement or otherwise to or with respect to the Executive other than for any entitlements under the terms of any other plans or programs of the Company in which the Executive participated and
under which the Executive has become entitled to a benefit. 
 (c) By the Company for Cause; By the Executive Other than for Good Reason. If
the Executive’s employment is terminated by the Company for Cause during the Employment Period, or the Executive voluntarily terminates employment during the Employment Period, other than for Good Reason, the Company shall pay the Executive, or
shall cause the Executive to be paid, the Executive’s base salary through the Date of Termination that has not been paid and the amount of any declared but unpaid bonuses, accrued but unpaid vacation pay, and unreimbursed employee business
expenses, and the Company shall have no further obligations under this Agreement or otherwise to or with respect to the Executive other than for any entitlements under the terms of any other plans or programs of the Company in which the Executive
participated and under which the Executive has become entitled to a benefit. 
 (d) Termination Pursuant to a Change of Control. If there is
a Change of Control, as defined in Section 5(d)(i) below, during the Term, the provisions of this Section 5(d) shall apply and shall continue to apply throughout the remainder of Employment Period. If, within one (1) year following a
Change of Control, the Executive’s employment is terminated by the Company or the Executive following the occurrence of any of the events listed in Section 5(d)(ii) below or if the Executive’s employment is terminated without cause
(in accordance with Section 5(a) above), the Company shall pay to the Executive (or the Executive’s estate, if applicable) the payments described under Section 5(a) and the Executive shall become vested in any outstanding options,
restricted stock, or other equity incentive award; provided that the Company’s obligation to make any payment, or to permit any vesting of outstanding options, restricted stock, or other equity incentive award as described above, shall be
conditioned upon the Executive’s execution, and non-revocation, of a written release, substantially in the form attached hereto as Exhibit 1. 
 (i) Change of Control shall mean the occurrence of one or more of the following events: 
 (A) any “person” (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becomes a “beneficial owner” (as such term is defined in Rule 13d-3
promulgated under the Exchange Act) (other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company, or any corporation owned, directly or indirectly, by the stockholders of the Company, in
substantially the same proportions as their ownership of stock of the Company), directly or indirectly, of securities of the Company, representing forty percent (40%) or more of the combined voting power of the Company’s then outstanding
securities; or 
 (B) persons who, as of the Effective Date, constituted the Company’s Board of Directors (the
“Incumbent Board”) cease for any reason including, without limitation, as a result of a tender offer, proxy contest, merger or similar transaction, to constitute at least a majority of the Board of Directors, provided that any person
becoming a director of the Company subsequent to the Effective Date whose election was approved by at least a majority of the directors then comprising the Incumbent Board shall, for purposes of this Section 5(d), be considered a member of the
Incumbent Board; or 
  

 5 

 (C) the stockholders of the Company approve a merger or consolidation of the Company
with any other corporation or other entity, other than (1) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by
being converted into voting securities of the surviving entity) more than forty percent (40%) of the combined voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or
consolidation or (2) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no “person” (as hereinabove defined) acquires more than forty percent (40%) of the combined
voting power of the Company’s then outstanding securities; or 
 (D) the stockholders of the Company approve a plan of
complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 
 (ii) The events referred to in Section 5(d) above shall be as follows: 
 (A) a
reduction of the Executive’s salary other than a reduction that (1) is based on the Company’s financial performance or (2) is similar to the reduction made to the salaries provided to all or most other senior executives of the
Company; or 
 (B) a significant change in the Executive’s responsibilities and/or duties which constitutes, when
compared to the Executive’s responsibilities and/or duties before the Change of Control, a demotion; or 
 (C) a
material loss of title or office; or 
 (D) the relocation of the offices at which the Executive is principally employed as
of the Change of Control to a location more than fifty (50) miles from such offices, which relocation is not approved by the Executive. 
 The Executive shall provide the Company with reasonable notice and an opportunity to cure any of the events listed in Section 5(d)(ii) and shall not be entitled to compensation pursuant to this Section 5(d)
unless the Company fails to cure within a reasonable period. 
 (e) Treatment of Payments Subject to Section 280G. It is the
understanding of the Executive and of the Company that certain payments by the Company to or for the benefit of the Executive under this Agreement or any other agreement or plan, if any, pursuant to which the Executive is entitled to receive
payments or benefits may be subject to the provisions of Section 280G of the Code or any like statutory or regulatory provision relating to parachute payments as such term is defined in section 280G(b)(2) of the Code (a “Parachute
Payment”). In general, under Section 280G, a Parachute Payment is a compensatory payment (including the accelerated vesting of compensatory stock options made upon the occurrence of a change in control of the Company) to the extent that
the payment exceeds three times the Executive’s annual compensation. 
  

 6 

 (i) Reduction of Minimal Parachute Payment. Notwithstanding any other provision of this
Agreement or any such agreement or plan, the amount of the payment pursuant to Section 5(d) hereof or any other payments (a “Change in Control Payment”) made to the Executive pursuant to a change in control as defined in
Section 280G that is treated as a Parachute Payment is less than 10% of the Change in Control Payment, such Change in Control Payment shall be reduced to an amount such that the Executive will not receive any Parachute Payment. To the extent
that such Parachute Payments have been made to or for the benefit of the Executive, the Executive shall refund such Parachute Payment to the Company with interest thereon at the applicable Federal rate determined under Section 1274(d) of the
Code, compounded annually, or at such other rate as may be required in order that no such payments shall subject to Section 280G or any like statutory or regulatory provision. To the extent that there is more than one method of reducing the
payments to bring them within the limitations of said Section 280G or any like statutory or regulatory provision, the Executive shall determine which method shall be followed, provided that if the Executive fails to make such determination
within forty-five (45) days after the Company has given notice of the need for such reduction, the Company may determine the method of such reduction in its sole discretion. 
 (ii) Payment of Tax Gross-Up for Substantial Parachute Payments. In the event that (i) the Company makes a Change in Control Payment
to the Executive under this Agreement or under any other arrangement that is determined to constitute a Parachute Payment and (ii) the amount of such Parachute Payment is 10% or more of the Change in Control Payment, the provisions of
Section 5(e)(i) shall not apply to such Parachute Payment and the Company shall pay to the Executive, prior to the time any excise tax imposed by section 4999 of the Code (“Excise Tax”) is payable with respect to such Payment, an
additional amount (the “Gross-Up Payment”) which, after the imposition of all income and excise taxes thereon (and assuming all federal, state and other income taxes are imposed at the highest marginal rate), is equal to the Excise Tax on
such Payment. 
 (iii) Determination of Parachute Payment Status. The determination of whether any Payment constitutes a
Parachute Payment and, if so, the amount, if any, to be paid by the Executive to the Company under Section 5(e)(i) hereof or to the Executive by the Company under Section 5(e)(ii) hereof and the time of payment pursuant to this
Section 5(e) shall be made by a nationally-recognized independent accounting firm (the “Auditor”) selected and paid for by the Company. Any Gross-Up Payment shall be paid by the Company to the Executive no later than ten calendar days
after the receipt of the Auditor’s determination. Any determination by the Auditor shall, subject to the provisions of Section 11(c)(ii) and (iii) below, be binding upon the Company and the Executive. 
 (iv) As a result of uncertainty in the application of sections 280G and 4999 of the Code, or other circumstances, at the time of the
initial determination by the Auditor hereunder, it is possible that the Gross-Up Payment made will have been an amount more than the Company should have paid pursuant to Section 5(e) (the “Overpayment”) or that the Gross-Up Payment
made will have been an amount less than the Company should have paid pursuant to Section 5(e) (the “Underpayment”). In the event that there is a final determination by the Internal Revenue Service, or a final determination by a court
of competent jurisdiction, with respect to the Executive’s liability under section 4999 of the Code such that an Overpayment has been made, then to the extent permitted by 

  

 7 

 
applicable law, the Executive agrees to return to the Company the amount of the Overpayment that the Executive recovers. In the event that there is a final
determination by the Internal Revenue Service, or a final determination by a court of competent jurisdiction with respect to the Executive’s liability under section 4999 of the Code such that an Underpayment arises under this Letter Agreement,
then any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive. 
 (v) The Executive
agrees to notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would result in a determination that an Overpayment or an Underpayment had occurred. Such notification shall be given as soon as practicable
but no later than 10 business days after the Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim. In the case of a claim that would result in an Underpayment, such notice shall include the date on
which such claim is requested to be paid. The Executive shall not pay such claim prior to the expiration of the 30 calendar day period following the date on which the Executive gives such notice to the Company (or such shorter period ending on the
date that any payment of taxes with respect to such claim is due). If the Company notifies the Executive in writing prior to the expiration of such period that it desires to contest such claim, the Executive shall cooperate with the Company provided
that the Company shall bear and pay directly all costs and expenses (including, without limitation, attorneys fees, additional interest and penalties) incurred in connection with such contest. 
 6. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit the Executive’s continuing or future participation in any plan,
program, policy or practice provided by the Company for which the Executive may qualify. Vested benefits and other amounts that the Executive is otherwise entitled to receive on or after the Date of Termination under any plan, policy, practice or
program of, or any contract or agreement with, the Company shall be payable in accordance with such plan, policy, practice, program, contract or agreement, as the case may be, except as explicitly modified by this Agreement. 
 7. No Mitigation. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts
payable to the Executive under any of the provisions of this Agreement and such amounts shall not be reduced, regardless of whether the Executive obtains other employment. 
 8. Confidential Information; Non-solicitation; Non-competition. 
 (a) The Executive agrees and acknowledges that by reason of his employment by and service to the Company, he will have access to, become exposed to and/or become knowledgeable about confidential information of the
Company (the “Confidential Information”) from time to time during the Employment Period, including, without limitation, proposals, plans, inventions, practices, systems, programs, processes, methods, techniques, research, records, supplier
sources, customer lists and other forms of business information that are not known to the Company’s competitors, are not recognized as being encompassed within standard business or management practices and/or are kept secret and confidential by
the Company. Executive agrees that at no time during or after the Employment Period will he disclose or use the Confidential Information except as may be required in the prudent course of business for the benefit of the Company. The Executive also
agrees to be subject to the Company’s Code of Ethics and Business Conduct as in effect from time to time during the Employment Period. 
  

 8 

 (b) The Executive acknowledges that the Company is generally engaged in business throughout the United
States. During the Executive’s employment by the Company and for eighteen months after the Date of Termination or the expiration of the final Employment Period, the Executive agrees that he will not, unless acting with the prior written consent
of the Company, directly or indirectly, own, manage, control, or participate in the ownership, management or control of, or be employed or engaged by, or otherwise affiliated or associated with, as an officer, director, employee, consultant,
independent contractor or otherwise, any other corporation, partnership, proprietorship, firm, association or other business entity, or otherwise engage in any business, which is engaged in hospital and long term care institutional pharmacy
services; provided, however, that the ownership of not more than 5% of the equity of a publicly traded entity shall not be deemed to be a violation of this paragraph. During such eighteen month period, Executive also agrees to make himself
reasonably available to the Company for consulting at a per diem rate that reflects his annual salary as in an effect prior to his termination of employment (plus reimbursement of Executive’s reasonable expenses). 
 (c) The Executive also agrees that he will not, directly or indirectly, during the period described in paragraph (b) of this Section 8 induce
any person who is an employee, officer, director, or agent of the Company, to terminate such relationship, or employ, assist in employing or otherwise be associated in business with any present or former employee or officer of the Company, including
without limitation those who commence such positions with the Company after the Date of Termination. 
 (d) The Executive also agrees that he
will not, directly or indirectly, during the period described in paragraph (b) of this Section 8, (i) solicit or otherwise accept business for hospital and long term care institutional pharmacy services from any client or customer of
the Company or any prospective client or customer of the Company or (ii) cause a client or customer, or any prospective client or customer of the Company, to terminate or otherwise modify adversely its business relationship with the Company.

 (e) The Executive acknowledges and agrees that the restrictions contained in this Section 8 are reasonable and necessary to protect
and preserve the legitimate interests, properties, goodwill and business of the Company, that the Company would not have entered into this Agreement in the absence of such restrictions and that irreparable injury will be suffered by the Company
should the Executive breach the provisions of this Section. The Executive represents and acknowledges that (i) the Executive has been advised by the Company to consult the Executive’s own legal counsel in respect of this Agreement,
(ii) the Executive has consulted with and been advised by his own counsel in respect of this Agreement, and (iii) the Executive has had full opportunity, prior to execution of this Agreement, to review thoroughly this Agreement with the
Executive’s counsel. 
 (f) The Executive further acknowledges and agrees that a breach of the restrictions in this Section 8 will
not be adequately compensated by monetary damages. The Executive agrees that actual damage may be difficult to ascertain and that, in the event of any such breach, the Company shall be entitled to injunctive relief in addition to such other legal or
equitable remedies as may be available to the Company. In the event that the provisions of this Section 8 should ever be adjudicated to exceed the limitations permitted by applicable law in any jurisdiction, it is the intention of the parties
that the provision shall be amended such that those provisions are made consistent with the maximum limitations permitted by applicable law, that such amendment shall apply only within the jurisdiction of the court that made such adjudication and
that those provisions otherwise be enforced to the maximum extent permitted by law. 
 (g) To the extent that any court action is permitted
consistent with or to enforce Section 9 of this Agreement, the Executive agrees that suit may be brought, and that he consents to 

  

 9 

 
personal jurisdiction, in the United States District Court for the Eastern District of Kentucky, or if such court does not have jurisdiction or will not
accept jurisdiction, in any court of general jurisdiction in Fayette County, Kentucky; consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding; and waives any objection which he may have to the laying of
venue of any such suit, action or proceeding in any such court. The Executive also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other papers. 
 (h) For purposes of this Section 8, the term “Company” shall be deemed to include subsidiaries and affiliates of the Company. 

(i) The Executive agrees that during his employment he shall not use or disclose to the Company any confidential or proprietary information obtained
in the course of employment with a prior employer. 
 9. Arbitration of Disputes. Any controversy or claim arising out of or relating to this
Agreement or the breach thereof or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise)
shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (“AAA”) in
Lexington, Kentucky in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the
Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement. Judgment upon the award rendered by the
arbitrator may be entered in any court having jurisdiction thereof. This Section 9 shall be specifically enforceable. Notwithstanding the foregoing, this Section 9 shall not preclude either party from pursuing a court action for the sole
purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 9.

 10. Successors. This Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable
by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives. This Agreement shall inure to the benefit of and be
binding upon the Company and its successors and assigns. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company
expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall
mean both the Company as defined above and any such successor that assumes and agrees to perform this Agreement, by operation of law or otherwise. 
 11. Miscellaneous. 
 (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of Kentucky, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified except by a written
agreement executed by the parties hereto or their respective successors and legal representatives. 
 (b) If a claim or action
at law or in equity is commenced to enforce or interpret the terms of this Agreement, including any claim or action pursuant to Section 8, and such claim or 

  

 10 

 
action is determined by the presiding fact-finder to be unreasonable, the prevailing party shall be entitled to recover, in addition to any other relief, all
attorney’s fees incurred by such prevailing party. 
 (c) All notices and other communications under this Agreement shall
be in writing and shall be given by hand to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
 If to the Executive, to the address on file with the Company. 
 If to the Company: 
 PharMerica Corporation 
 1901 Campus Place, Louisville, KY 40299 
 or to such other address as either party furnishes to the other in writing in accordance with this paragraph (c) of Section 11. Notices and
communications shall be effective when actually received by the addressee. 
 (d) The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. If any provision of this Agreement shall be held invalid or unenforceable in part, the remaining portion of such provision,
together with all other provisions of this Agreement, shall remain valid and enforceable and continue in full force and effect to the fullest extent consistent with law. 
 (e) Notwithstanding any other provision of this Agreement, the Company may withhold from amounts payable under this Agreement all federal,
state, local, and foreign taxes that are required to be withheld by applicable laws or regulations. 
 (f) The
Executive’s or the Company’s failure to insist upon strict compliance with any provision of, or to assert any right under, this Agreement (including, without limitation, the right of the Executive to terminate employment for Good Reason
pursuant to paragraph (c) of Section 5 of this Agreement) shall not be deemed to be a waiver of such provision or right or of any other provision of or right under this Agreement. 
 (g) Anything to the contrary herein notwithstanding, all benefits or payments provided by the Company to the Executive that would be
deemed to constitute “nonqualified deferred compensation” within the meaning of Section 409A are intended to comply with Section 409A of the Code. If, however, any such benefit or payment is deemed to not comply with
Section 409A of the Code, the Company and the Executive agree to renegotiate in good faith any such benefit or payment (including, without limitation, as to the timing of any severance payments payable hereof) so that either
(i) Section 409A of the Code will not apply or (ii) compliance with Section 409A will be achieved. 
 (h)
This Agreement constitutes the entire agreement between the parties with respect to the subject matter of the Agreement and supercedes all prior agreements between the parties with respect to any related subject matter. 
 (i) This Agreement may be executed in several counterparts, each of which shall be deemed an original, and said counterparts shall
constitute but one and the same instrument. 
  

 11 

 12. The respective rights and obligations of the parties hereunder shall survive any termination of the
Executive’s employment to the extent necessary to the intended preservation of such rights and obligations, including, but not by way of limitation, those rights and obligations set forth in Sections 3, 5, 6, 8, 9, and 11. 
 {SIGNATURE ON NEXT PAGE} 
 IN WITNESS
WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the authorization of the Committee, the Company has caused this Agreement to be executed in its name on its behalf, all as of the day and year first above written.

  

									
	 	 	SAFARI HOLDING CORPORATION
				
		 	 By:
  
	 		 	 /s/ Gregory Weishar
  

		 	 Name:
  
	 		 	 Gregory Weishar
  

		 	 Title:
  
	 		 	 Chief Executive Officer
  

		
		 	EXECUTIVE
		
		 	 /s/ Michael Culotta
  

		 	Michael Culotta

  

 12 

 EXHIBIT 1 
 SEPARATION OF EMPLOYMENT AGREEMENT 
 AND GENERAL RELEASE 
 THIS SEPARATION OF EMPLOYMENT AGREEMENT AND GENERAL RELEASE (the “Agreement”) is made as of this      day of
                    ,         , by and between PharMerica Corporation (the “Company”)
and                      (the “Executive”). 
 WHEREAS, Executive formerly was employed as                     ; 
 WHEREAS, Executive and Company entered into an Employment Agreement, dated
                         ,         , (the “Employment
Agreement”) which provides for certain severance benefits in the event that Executive’s employment is terminated on account of a reason set forth in the Employment Agreement; 
 WHEREAS, Executive and the Company mutually desire to terminate Executive’s employment on an amicable basis, such termination to be effective
                         ,          (the “Date of
Resignation”); and 
 WHEREAS, in connection with the termination of Executive’s employment, the parties have agreed to a
separation package and the resolution of any and all disputes between them. 
 NOW, THEREFORE, IT IS HEREBY AGREED by and between Executive
and the Company as follows: 
 1.(a) Executive, for and in consideration of the commitments of the Company as set forth in Paragraph 5 of this
Agreement, and intending to be legally bound, does hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company, its affiliates, subsidiaries and parents, and its officers, directors, employees, and agents, and its and their respective successors and
assigns, heirs, executors, and administrators (each, a “Releasee” and collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity, which Executive ever had, now has, or
hereafter may have, whether known or unknown, or which Executive’s heirs, executors, or administrators may have, by reason of any matter, cause or thing whatsoever, from the beginning of Executive’s employment to the date of this
Agreement, and particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to Executive’s employment relationship with the Company and/or its predecessors, subsidiaries or affiliates, the
terms and conditions of that employment relationship, and the termination of that employment relationship, including, but not limited to, any claims arising under the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act
(“OWBPA”), Title VII of The Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, the Kentucky Civil Rights Act, and any other claims
under any federal, state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs. This Agreement is effective without regard to the legal nature of the claims raised and
without regard to whether any such claims are based upon tort, equity, implied or express contract or discrimination of any sort. 
 (b) To
the fullest extent permitted by law, and subject to the provisions of Paragraph 10 below, Executive represents and affirms that (i) Executive has not filed or caused to be filed on Executive’s behalf any claim for relief against the
Company or any Releasee and, to the best of Executive’s knowledge and belief, no outstanding claims for relief have been filed or asserted against the 

  

 13 

 
Company or any Releasee on Executive’s behalf; (ii) Executive has not reported any improper, unethical or illegal conduct or activities to any
supervisor, manager, department head, human resources representative, agent or other representative of the Company, to any member of the Company’s legal or compliance departments, or to the ethics hotline, and has no knowledge of any such
improper, unethical or illegal conduct or activities; and (iii) Executive will not file, commence, prosecute or participate in any judicial or arbitral action or proceeding against the Company or any Releasee based upon or arising out of any
act, omission, transaction, occurrence, contract, claim or event existing or occurring on or before the date of this Agreement. 
 (c)
Nothing in the Agreement will be deemed to release the Company from (i) claims solely to enforce this Agreement, (ii) claims for indemnification under the Company’s By-Laws, or (iii) claims for payment or reimbursement pursuant
to any employee benefit plan, policy or arrangement of the Company. 
 2. In consideration of the Company’s agreements as set forth in
Paragraph 5 herein, Executive agrees to be bound by the terms of Section 9 of the Employment Agreement. 
 3. Executive agrees and
recognizes that Executive has permanently and irrevocably severed Executive’s employment relationship with the Company, that Executive shall not seek employment with the Company or any affiliated entity at any time in the future, and that the
Company has no obligation to employ Executive in the future. 
 4. Executive further agrees that Executive will not disparage or subvert the
Company, or make any statement reflecting negatively on the Company, its affiliated corporations or entities, or any of their officers, directors, employees, agents or representatives, including, but not limited to, any matters relating to the
operation or management of the Company, Executive’s employment and the termination of Executive’s employment, irrespective of the truthfulness or falsity of such statement. The Company agrees that none of its officers, directors,
employees, agents or representatives will disparage or subvert the Executive, or make any statement reflecting negatively on the Executive, including, but not limited to, any matters relating to the Executive’s performance or the termination of
Executive’s employment, irrespective of the truthfulness or falsity of such statement. 
 5. In consideration for Executive’s
agreement as set forth herein, the Company agrees that the Company shall provide the following: 
 (a) The severance benefits
described in Section 5 of the Employment Agreement; and 
 (b) The Company will maintain, for no less than 6 years
following the Date of Resignation, directors’ and officers’ liability insurance covering the Executive’s potential liability in connection with his employment by the Company in amounts and on terms that are commensurate with the
coverage provided to its active officers and directors of the Company. 
 6. Executive understands and agrees that the payments, benefits and
agreements provided in this Agreement are being provided to Executive in consideration for Executive’s acceptance and execution of, and in reliance upon Executive’s representations in, this Agreement. Executive acknowledges that if
Executive had not executed this Agreement containing a release of all claims against the Company, Executive would only have been entitled to the payments provided in the Company’s standard severance pay plan for employees. 
  

 14 

 7. Executive acknowledges and agrees that the Company previously has satisfied any and all obligations
owed to Executive under any employment agreement or offer letter Executive has with the Company and, further, that this Agreement supersedes any employment agreement or offer letter Executive has with the Company, and any and all prior agreements or
understandings, whether written or oral, between the parties shall remain in full force and effect to the extent not inconsistent with this Agreement, and further, that, except as set forth expressly herein, no promises or representations have been
made to Executive in connection with the termination of Executive’s employment agreement or offer letter with the Company, or the terms of this Agreement. 
 8. Executive agrees not to disclose the terms of this Agreement to anyone, except Executive’s spouse, attorney and, as necessary, tax/financial advisor. Likewise, the Company agrees that the terms of this
Agreement will not be disclosed except as may be necessary to obtain approval or authorization to fulfill its obligations hereunder or as required by law. It is expressly understood that any violation of the confidentiality obligation imposed
hereunder constitutes a material breach of this Agreement. 
 9. Executive represents that Executive does not presently have in
Executive’s possession any records and business documents, whether on computer or hard copy, and other materials (including but not limited to computer disks and tapes, computer programs and software, office keys, correspondence, files,
customer lists, technical information, customer information, pricing information, business strategies and plans, sales records and all copies thereof) (collectively, the “Corporate Records”) provided by the Company and/or its predecessors,
subsidiaries or affiliates or obtained as a result of Executive’s prior employment with the Company and/or its predecessors, subsidiaries or affiliates, or created by Executive while employed by or rendering services to the Company and/or its
predecessors, subsidiaries or affiliates. Executive acknowledges that all such Corporate Records are the property of the Company. In addition, Executive shall promptly return in good condition any and all beepers, credit cards, cellular telephone
equipment, business cards and computers. As of the Date of Resignation, the Company will make arrangements to remove, terminate or transfer any and all business communication lines including network access, cellular phone, fax line and other
business numbers. 
 10. Nothing in this Agreement shall prohibit or restrict Executive from: (i) making any disclosure of information
required by law; (ii) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by, any federal regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the
Company’s General Counsel or Human Resources Director; or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an alleged violation of any federal, state or municipal law relating to fraud, or any
rule or regulation of the Securities and Exchange Commission or any self-regulatory organization. 
 11. The parties agree and acknowledge
that the agreement by the Company described herein, and the settlement and termination of any asserted or unasserted claims against the Releasees, are not and shall not be construed to be an admission of any violation of any federal, state or local
statute or regulation, or of any duty owed by any of the Releasees to Executive. 
 12. Executive agrees and recognizes that should Executive
breach any of the obligations or covenants set forth in this Agreement, the Company will have no further obligation to provide Executive with the consideration set forth herein, and will have the right to seek repayment of all consideration paid up
to the time of any such breach. Further, Executive acknowledges in the event of a breach of this Agreement, Releasees may seek any and all appropriate relief for any such breach, including equitable relief and/or money damages, attorney’s fees
and costs. 
  

 15 

 13. Executive further agrees that the Company shall be entitled to preliminary and permanent injunctive
relief, without the necessity of proving actual damages, as well as to an equitable accounting of all earnings, profits and other benefits arising from any violations of this Agreement, which rights shall be cumulative and in addition to any other
rights or remedies to which the Company may be entitled. 
 14. This Agreement and the obligations of the parties hereunder shall be
construed, interpreted and enforced in accordance with the laws of the State of Kentucky. 
 15. Executive certifies and acknowledges as
follows: 
 (a) That Executive has read the terms of this Agreement, and that Executive understands its terms and effects, including the fact
that Executive has agreed to RELEASE AND FOREVER DISCHARGE the Company and each and everyone of its affiliated entities from any legal action arising out of Executive’s employment relationship with the Company and the termination of that
employment relationship; 
 (b) That Executive has signed this Agreement voluntarily and knowingly in exchange for the consideration
described herein, which Executive acknowledges is adequate and satisfactory to Executive and which Executive acknowledges is in addition to any other benefits to which Executive is otherwise entitled; 
 (c) That Executive has been and is hereby advised in writing to consult with an attorney prior to signing this Agreement; 
 (d) That Executive does not waive rights or claims that may arise after the date this Agreement is executed; 
 (e) That the Company has provided Executive with a period of twenty-one (21) days within which to consider this Agreement, and that Executive has
signed on the date indicated below after concluding that this Agreement is satisfactory to Executive; and 
 (f) Executive acknowledges that
this Agreement may be revoked by Executive within seven (7) days after execution, and it shall not become effective until the expiration of such seven day revocation period. In the event of a timely revocation by Executive, this Agreement will
be deemed null and void and the Company will have no obligations hereunder. 
 [SIGNATURE PAGE FOLLOWS] 
  

 16 

 Intending to be legally bound hereby, Executive and the Company executed the foregoing Separation of
Employment Agreement and General Release this      day of                     ,
        . 
  

							
	  
	 	Witness:	 	  

	[Executive]	 		 	
			
	PHARMERICA CORPORATION	 		 	
				
	By:	 	  
	 	Witness:	 	  

				
	Name:	 	  
	 		 	
				
	Title:	 	  
	 		 	

  

 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]